Context: In clinical and real-world studies, mepolizumab is well tolerated with a favorable benefit-risk profile in patients with severe eosinophilic asthma (SEA); longer-term real-world safety data are required.
No takes yet. Share an insight, caveat, or question.
Pavord et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: